Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing.

Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.

[1]  Salvatore DiMauro,et al.  Nuclear power and mitochondrial disease , 1998, Nature Genetics.

[2]  J. Christodoulou,et al.  Leigh syndrome: Clinical features and biochemical and DNA abnormalities , 1996, Annals of neurology.

[3]  R. Carrozzo,et al.  A new method for analysis of mitochondrial DNA point mutations and assess levels of heteroplasmy. , 2006, Biochemical and biophysical research communications.

[4]  R. Rodenburg,et al.  The mitochondrial 13513G>A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolff–Parkinson–White , 2007, European Journal of Human Genetics.

[5]  K. Huoponen,et al.  A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. , 1991, American journal of human genetics.

[6]  A. Harding,et al.  A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. , 1990, American journal of human genetics.

[7]  H Tanke,et al.  Simultaneous A8344G heteroplasmy and mitochondrial DNA copy number quantification in myoclonus epilepsy and ragged-red fibers (MERRF) syndrome by a multiplex molecular beacon based real-time fluorescence PCR. , 2001, Nucleic acids research.

[8]  A. Syvänen,et al.  Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing. , 1999, Methods in molecular medicine.

[9]  D. Turnbull,et al.  Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. , 1997, Brain : a journal of neurology.

[10]  M. Holland,et al.  A sensitive denaturing gradient-Gel electrophoresis assay reveals a high frequency of heteroplasmy in hypervariable region 1 of the human mtDNA control region. , 2000, American journal of human genetics.

[11]  S. Dimauro,et al.  MELAS: Clinical features, biochemistry, and molecular genetics , 1992, Annals of neurology.

[12]  D. Wallace.  Mitochondrial diseases in man and mouse. , 1999, Science.

[13]  N. Hamasaki,et al.  High-sensitivity detection of the A3243G mutation of mitochondrial DNA by a combination of allele-specific PCR and peptide nucleic acid-directed PCR clamping. , 2004, Clinical chemistry.

[14]  M. Wołoszyńska,et al.  Heteroplasmy as a common state of mitochondrial genetic information in plants and animals , 2006, Current Genetics.

[15]  S. Dimauro,et al.  Heterogeneous clinical presentation of the mtDNA NARP/T8993G mutation , 1997, Neurology.

[16]  A. Syvänen,et al.  Heteroplasmy of the human mtDNA control region remains constant during life. , 2001, American journal of human genetics.

[17]  Lee-Jun C Wong,et al.  Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. , 2004, Clinical chemistry.

[18]  Robert W. Taylor,et al.  Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. , 2002, Nucleic acids research.

[19]  H. Dahl,et al.  Mitochondrial disorders: genetics, counseling, prenatal diagnosis and reproductive options. , 2001, American journal of medical genetics.

[20]  K. Wakabayashi,et al.  Quantitation of heteroplasmy of mitochondrial trnaLeu(UUR) gene using PCR‐SSCP , 1995, Muscle & nerve.

[21]  N. Shimizu,et al.  Rapid quantification of the heteroplasmy of mutant mitochondrial DNAs in Leber's hereditary optic neuropathy using the Invader technology. , 2004, Clinical biochemistry.

[22]  L. Wong,et al.  Yield of mtDNA mutation analysis in 2,000 patients. , 1998, American journal of medical genetics.

[23]  L. Wong,et al.  Direct detection of multiple point mutations in mitochondrial DNA. , 1997, Clinical chemistry.

[24]  White,et al.  Novel Mitochondrial DNA Variant That May Give a False Positive Diagnosis for the T8993C Mutation. , 1998, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[25]  F. Schwarz,et al.  Design and use of a peptide nucleic acid for detection of the heteroplasmic low-frequency mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) mutation in human mitochondrial DNA. , 2002, Clinical chemistry.

[26]  A. Hattersley,et al.  Rapid and sensitive real-time polymerase chain reaction method for detection and quantification of 3243A>G mitochondrial point mutation. , 2006, The Journal of molecular diagnostics : JMD.

[27]  A. Syvänen,et al.  Quantification of point mutations associated with Leber hereditary optic neuroretinopathy by solid-phase minisequencing , 2004, Human Genetics.

[28]  S. Dimauro,et al.  Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993. , 1999, American journal of human genetics.

[29]  D R Johns,et al.  An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. , 1992, Biochemical and biophysical research communications.

[30]  N. Shimizu,et al.  Quantitative determination of heteroplasmy in Leber's hereditary optic neuropathy by single-strand conformation polymorphism. , 1995, Investigative ophthalmology & visual science.

[31]  Kirby,et al.  A False-Positive Diagnosis for the Common MELAS (A3243G) Mutation Caused by a Novel Variant (A3426G) in the ND1 Gene of Mitochondria DNA. , 1998, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[32]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[33]  E. Shoubridge,et al.  Variable distribution of mutant mitochondria1 DNAs (tRNALeu[3243]) in tissues of symptomatic relatives with MELAS , 1993, Neurology.

[34]  D. Wallace,et al.  Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. , 1988, Science.

[35]  S. Dimauro,et al.  Clinical features associated with the A → G transition at nucleotide 8344 of mtDNA (“MERRF mutation”) , 1993, Neurology.